ADMA Biologics, Inc. (ADMA) stock
ADMANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 17/3028% below fair value
$13.63+0.16 (+1.19%)
Close on Nov 17, 2026Market cap $3.05BP/E 19.5Yield –
ADMA Biologics total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
ADMA Biologics's total debt was $196.59M at Jun 30, 2026. For fiscal 2025 it was $72.14M, down 0.3% from the year before. Over ten years it grew 34.3% a year on average. The highest annual figure on record is $92.97M in fiscal 2020.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $72.14M | -0.3% |
| FY2024 | Dec 31, 2024 | $72.34M | -22.2% |
| FY2020 | Dec 31, 2020 | $92.97M | +36.1% |
| FY2019 | Dec 31, 2019 | $68.29M | +158.3% |
| FY2018 | Dec 31, 2018 | $26.44M | +4.2% |
| FY2017 | Dec 31, 2017 | $25.37M | +105.9% |
| FY2016 | Dec 31, 2016 | $12.32M | -13.5% |
| FY2015 | Dec 31, 2015 | $14.25M | -2.2% |
| FY2014 | Dec 31, 2014 | $14.57M | +199.4% |
| FY2013 | Dec 31, 2013 | $4.87M | +28.9% |
| FY2012 | Dec 31, 2012 | $3.77M | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $196.59M | +171.8% |
| Q1 FY2026 | Mar 31, 2026 | $196.87M | +110.7% |
| Q4 FY2025 | Dec 31, 2025 | $72.14M | -22.4% |
| Q3 FY2025 | Sep 30, 2025 | $72.43M | -11.8% |
| Q4 FY2024 | Dec 31, 2024 | $72.34M | -11.4% |
| Q1 FY2021 | Mar 31, 2021 | $93.41M | +15.0% |
| Q4 FY2020 | Dec 31, 2020 | $92.97M | +36.1% |
| Q3 FY2020 | Sep 30, 2020 | $82.11M | +21.0% |
| Q2 FY2020 | Jun 30, 2020 | $81.65M | +21.0% |
| Q1 FY2020 | Mar 31, 2020 | $81.21M | +98.6% |
| Q4 FY2019 | Dec 31, 2019 | $68.29M | +158.3% |
| Q3 FY2019 | Sep 30, 2019 | $67.84M | +159.4% |
| Q2 FY2019 | Jun 30, 2019 | $67.47M | +160.7% |
| Q1 FY2019 | Mar 31, 2019 | $40.89M | +59.6% |
| Q4 FY2018 | Dec 31, 2018 | $26.44M | +4.2% |
| Q3 FY2018 | Sep 30, 2018 | $26.15M | +79.9% |
| Q2 FY2018 | Jun 30, 2018 | $25.88M | +176.5% |
| Q1 FY2018 | Mar 31, 2018 | $25.62M | +136.2% |
| Q4 FY2017 | Dec 31, 2017 | $25.37M | +105.9% |
| Q3 FY2017 | Sep 30, 2017 | $14.53M | +5.4% |
| Q2 FY2017 | Jun 30, 2017 | $9.36M | – |
| Q1 FY2017 | Mar 31, 2017 | $10.85M | – |
| Q4 FY2016 | Dec 31, 2016 | $12.32M | – |
| Q3 FY2016 | Sep 30, 2016 | $13.79M | – |
See a number that looks wrong?